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Clinical PerspectiveWhat Is New?Our study of Japanese atomic‐bomb survivors with \<4 Gy whole‐body radiation exposures is the first to investigate the long‐term risk of peripheral artery disease after irradiation.A relationship between radiation exposure and the prevalence of peripheral artery disease was not evident.Prolonged upstroke time, a sensitive marker for stenosis, was correlated with radiation dose, but the association was not statistically significant (*P*=0.091).What Are the Clinical Implications?Widespread use of radiographic procedures in medicine has led to concerns over possible cardiovascular effects.Whether there is a risk of peripheral artery disease after low‐to‐moderate irradiation has been unclear.A radiation dose response for upstroke time could not be ruled out and warrants further study.

 {#jah33655-sec-0008}

Epidemiological studies of the atomic bomb survivors have reported that low‐to‐moderate high‐dose‐rate radiation exposures are associated with an elevated risk of cardiovascular disease.[1](#jah33655-bib-0001){ref-type="ref"}, [2](#jah33655-bib-0002){ref-type="ref"} In contrast, inconsistent results have been reported from studies of low‐to‐moderate irradiated populations in low‐dose‐rate occupational and environmental settings,[3](#jah33655-bib-0003){ref-type="ref"}, [4](#jah33655-bib-0004){ref-type="ref"} so the effects of lower doses of radiation on cardiovascular disease outcomes are not yet clear. Estimated disease risks do not directly address questions regarding radiation‐related tissue effects, knowledge of which is important for establishing a causal association.

Peripheral artery disease (PAD), together with coronary artery disease and cerebrovascular disease, develops as polyvascular atherosclerosis. Atherosclerosis is an inflammatory process associated with endothelial damage and dysfunction, and it is the major cause of vascular death. One pathway leading to atherosclerosis development might be shared with radiation‐related tissue effects in the circulatory system.[5](#jah33655-bib-0005){ref-type="ref"} Development of systemic atherosclerosis or PAD subsequent to radiation exposure may be plausible,[6](#jah33655-bib-0006){ref-type="ref"} although such an association has not been investigated thoroughly. It has been demonstrated that a more sensitive tool is needed to assess population rates of lower‐extremity PAD.

Our aim was to examine the association between radiation dose and PAD prevalence among atomic bomb survivors in the AHS (Adult Health Study) from the Radiation Effects Research Foundation between 2010 and 2014. This is the first clinical survey of survivors, made with noninvasive ankle‐brachial blood pressure index, allowing us to properly investigate radiation‐related PAD prevalence.

Methods {#jah33655-sec-0009}
=======

The data, analytic methods, and study materials will not be made available to other researchers for purposes of reproducing the results or replicating the procedure.

Participants {#jah33655-sec-0010}
------------

The Radiation Effects Research Foundation established in 1958 the AHS cohort of 19 961 survivors of the atomic bombings of Hiroshima and Nagasaki. Along with complete follow‐up with respect to death (based on vital statistics data), health examinations have been performed biennially, and \>70% of the cohort continue to reside in areas accessible to our facilities and continue to participate. Participants in this study were divided into 2 groups: the primary cohort, which consists of the original‐ and extended‐AHS cohort members whose health examinations started from 1958 or 1977, respectively, and an expansion of the cohort comprising 1961 survivors exposed to atomic‐bomb radiation at less than 10 years of age, which was added in 2008 to augment the study of effects of low‐to‐moderate doses.[7](#jah33655-bib-0007){ref-type="ref"}, [8](#jah33655-bib-0008){ref-type="ref"} In addition to the summary of all participants (Table [1](#jah33655-tbl-0001){ref-type="table"}), the features of the two groups are compared (Table [2](#jah33655-tbl-0002){ref-type="table"}).

###### 

Baseline Characteristics Across Radiation Dose Categories: The Adult Health Study (N=3476)

  Covariates                            Overall        DS02 R1 Skin Dose \[Gy\]   *P* Value for Homogeneity Test[a](#jah33655-note-0002){ref-type="fn"}                                                                  
  ------------------------------------- -------------- -------------------------- ----------------------------------------------------------------------- --------------- --------------- --------------- -------------- ---------
  Age, y                                74.8 (6.4)     80.4 (5.8)                 75.2 (6.3)                                                              72.6 (5.3)      76.9 (7.0)      77.8 (6.5)      76.4 (7.0)     \<0.001
  Age at radiation exposure, y          8.5 (6.2)      14.5 (5.6)                 8.9 (6.1)                                                               6.3 (5.1)       10.7 (6.8)      11.5 (6.5)      10.0 (6.8)     \<0.001
  Body mass index, kg/m^2^              22.9 (3.4)     22.3 (3.35)                23.0 (3.5)                                                              23.1 (3.3)      22.9 (3.0)      22.2 (3.7)      22.2 (3.1)     \<0.001
  Systolic blood pressure, mm Hg        132.1 (17.4)   134.4 (17.7)               132.5 (17.0)                                                            131.0 (17.1)    132.4 (17.8)    132.3 (19.3)    136.3 (17.3)   0.0034
  Diastolic blood pressure, mm Hg       73.9 (10.4)    71.4 (10.1)                74.2 (10.6)                                                             74.9 (10.2)     73.0 (9.9)      70.2 (11.1)     71.3 (10.2)    \<0.001
  Total cholesterol, mm Hg              203.8 (34.1)   199.7 (30.9)               202.4 (34.9)                                                            207.5 (34.2)    198.5 (33.0)    199.2 (32.3)    199.5 (34.8)   \<0.001
  HDL‐cholesterol, mg/dL                59.5 (15.4)    58.8 (15.2)                59.4 (15.3)                                                             60.4 (15.5)     57.3 (14.5)     59.4 (15.2)     56.4 (16.1)    0.0137
  LDL‐cholesterol, mg/dL                115.2 (28.9)   111.9 (26.1)               114.1 (28.9)                                                            118.0 (29.3)    112.3 (28.0)    111.5 (28.5)    112.2 (28.2)   \<0.001
  Triglyceride, g/dL                    122.0 (69.3)   111.7 (55.4)               118.3 (63.3)                                                            124.7 (73.4)    128.2 (65.3)    119.0 (70.2)    142.9 (91.9)   \<0.001
  White blood cell, ×100/dL             55.3 (15.7)    53.0 (13.4)                54.7 (15.5)                                                             55.6 (16.0)     56.4 (14.8)     56.0 (18.2)     57.8 (15.6)    0.0372
  C‐reactive protein, μg/L              0.18 (0.65)    0.19 (0.54)                0.18 (0.55)                                                             0.16 (0.36)     0.28 (1.77)     0.22 (0.53)     0.17 (0.36)    0.1856
  HbA1c, %                              6.13 (0.75)    6.07 (0.64)                6.08 (0.71)                                                             6.15 (0.78)     6.18 (0.85) (   6.14 (0.7)      6.32 (0.94)    0.0139
  Upstroke time, ms                     144.3 (23.9)   146.2 (23.1)               143.0 (23.0)                                                            143.8 (23.2 )   146.9 (26.7)    147.9 (27.8 )   150.7 (29.5)   0.0036
  Ankle‐brachial index                  1.13 (0.07)    1.14 (0.08)                1.14 (0.07)                                                             1.13 (0.07)     1.14 (0.07)     1.13 (0.07)     1.13 (0.08)    0.1956
  Estimated GFR, mL/min per 1.73 m^2^   67.5 (16.9)    62.9 (17.1)                67.0 (17.0)                                                             69.3 (15.9)     65.9 (18.1)     64.8 (17.8)     66.4 (20.8)    \<0.001
                                        n (%)          n (%)                      n (%)                                                                   n (%)           n (%)           n (%)           n (%)          n (%)
  Male sex                              1427 (41.1)    84 (32.4)                  457 (40.2)                                                              661 (43.7 )     87 (36.0)       96 (42.1)       42 (42.4)      0.0085
  Diabetes mellitus                     754 (21.7)     51 (19.7)                  228 (20.1)                                                              339 (22.4)      53 (21.9)       51 (22.4)       32 (32.3)      0.0908
  Hypertension                          2288 (65.8)    183 (70.7)                 761 (67.0)                                                              933 (61.7)      178 (73.6)      161 (70.6)      72 (72.7)      \<0.001
  Dyslipidemia                          2264 (65.1)    149 (57.5)                 716 (63.0)                                                              1032 (68.3)     161 (66.5)      138 (60.5)      68 (68.7)      0.0027
  Smoking status                                                                                                                                                                                                         
  Never                                 2044 (59.0)    173 (66.8)                 669 (59.1)                                                              868 (57.5)      150 (62.2)      129 (57.3)      55 (55.6)      0.0184
  Past                                  1130 (32.6)    74 (28.6)                  370 (32.7)                                                              495 (32.8)      71 (29.5)       78 (34.7)       42 (42.4)      
  Current                               291 (8.4)      12 (4.6)                   93 (8.2)                                                                146 (9.7)       20 (8.3)        18 (8.0)        2 (2.0)        

Continuous variables are summarized by the mean (SD); categorical data are summarized by participant number and proportion (%). GFR indicates glomerular filtration rate; HbA1c, hemoglobin A1c; HDL, high‐density lipoprotein; LDL, low‐density lipoprotein.

*P* values are from χ^2^ tests for the equality of proportions or *t* tests for the equality of means.
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###### 

Variable Distributions in the Primary Cohort and the Expansion Group

                                       Primary Cohort   Expansion Group   *P* Value for Homogeneity test[a](#jah33655-note-0004){ref-type="fn"}
  ------------------------------------ ---------------- ----------------- -----------------------------------------------------------------------
  Total cholesterol, mg/dL             200.05 (34.45)   207.93 (33.87)    \<0.001
  HDL‐cholesterol, mg/dL               58.28 (15.08)    60.77 (15.55)     \<0.001
  LDL‐cholesterol, mg/dL               112.77 (28.61)   118.02 (29.28)    \<0.001
  Triglyceride                         120.97 (66.11)   124.54 (73.27)    0.0429
  White blood cell count, ×100/dL      55.48 (15.79)    55.38 (15.96)     0.6708
  hsCRP, μg/L                          0.19 (0.49)      0.18 (0.77)       0.5564
  HbA1c, %                             6.10 (0.75)      6.16 (0.77)       0.0194
  Age at examination, y                78.24 (6.57)     70.72 (2.69)      \<0.001
  Age at radiation exposure, y         11.80 (6.40)     4.53 (2.60)       \<0.001
  Body mass index, kg/m^2^             22.69 (3.46)     23.22 (3.28)      \<0.001
  Upstroke time                        147.87 (26.60)   141.19 (21.15)    \<0.001
  Ankle‐brachial index                 1.13 (0.07)      1.14 (0.07)       0.092
  Systolic blood pressure, mm Hg       133.55 (17.94)   130.32 (16.58)    \<0.001
  Diastolic blood pressure, mm Hg      72.25 (10.93)    75.75 (9.69)      \<0.001
  estimate GFR, mL/min per 1.73 m^2^   65.09 (17.89)    70.29 (15.36)     \<0.001
  Hiroshima, %                         54.2             68.1              \<0.001
  Diabetes mellitus, %                 21.5             21.9              0.8147
  Hypertension, %                      70.9             60.5              \<0.001
  Dyslipidemia, %                      63.4             67.0              0.0246
  Never, %                             61.5             56.3              \<0.001
  Ever, %                              32.0             33.3              
  Current, %                           6.5              10.4              

Continuous variables are summarized by the mean and SD; categorical data are summarized by the participant number and proportion (%). GFR indicates glomerular filtration rate; HbA1c, hemoglobin A1c; HDL, high‐density lipoprotein; hsCRP, high‐sensitivity C‐reactive protein; LDL, low‐density lipoprotein.

*P* values are from χ^2^ tests for the equality of proportions or *t* tests for the equality of means.
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During the period 2010 to 2014, 3757 participants were scheduled for inclusion in this study, where 8 people known to be undergoing hemodialysis were not invited to participate because placing cuffs on their upper extremities in the conduct of the study might result in vascular access‐related complications. Because 281 invited people refused, there were 3476 people who participated (92.5% participation). Because radiation dose estimates were missing for 259 participants, 3217 participants were available for analyses. The study protocol was approved by the institutional review board of the Radiation Effects Research Foundation, and all participants gave written informed consent.

Ankle‐Brachial Index, Upstroke Time, and Prevalent PAD {#jah33655-sec-0011}
------------------------------------------------------

Ankle‐brachial index (ABI) is the ratio of systolic blood pressure in the ankle to that in the arm. A randomly assigned technician obtained the ABI by using an automated oscillometric device, VP‐2000 (Omron Healthcare, Kyoto, Japan). The measurement protocol and data validation for ABI are described elsewhere.[9](#jah33655-bib-0009){ref-type="ref"} Prevalent PAD was declared if a participant met either of 2 criteria: (1) ABI≤1.0, including borderline ABI (0.91--0.99[10](#jah33655-bib-0010){ref-type="ref"}); and (2) a self‐reported prior history of revascularization identified by *International Classification of Diseases, Tenth Revision (ICD‐10)* codes I70.2 and I70.9 stored in our clinical‐examination database. Leg symptoms were not considered in the PAD diagnosis. Because prolonged upstroke time (UT) from pulse wave analysis using VP‐2000 has not been established as a diagnostic criteria for PAD,[11](#jah33655-bib-0011){ref-type="ref"} in the current study we considered prolonged UT merely as a marker of arterial damage.

Atherosclerosis Risk Factors and Cardiovascular Disease {#jah33655-sec-0012}
-------------------------------------------------------

Potential confounding variables included smoking history, systolic and diastolic blood pressure, high‐sensitivity C‐reactive protein, white blood cell count, body mass index, nonfasting total cholesterol, low‐density lipoprotein cholesterol, high‐density lipoprotein cholesterol, triglycerides, estimated glomerular filtration rate (based on serum creatinine level), and indicators of 3 existing clinical conditions: hypertension, diabetes mellitus, and dyslipidemia. People with any of the latter 3 clinical conditions were also surveyed as to whether or not they were taking medication for treatment of these disorders. Smoking status was defined as never, past, or current. Body mass index (kg/m^2^) was calculated from the participant\'s height and weight at the examination. The high‐sensitivity C‐reactive protein and serum creatinine levels were determined by using a chemiluminescent ELISA (Nissui, Tokyo, Japan); all measurements were made according to an automated procedure (Hitachi 7170S; Hitachi Ltd, Tokyo, Japan) under defined quality control criteria. Estimated glomerular filtration rate was derived from serum creatinine level using the formula \[194×creatinine−1.094×Age−0.287 (×0.739 only for women)\].[12](#jah33655-bib-0012){ref-type="ref"} Hypertension was defined as having auscultatory systolic blood pressure ≥140 mm Hg, having diastolic blood pressure ≥90 mm Hg, or being under treatment for high blood pressure. Diabetes mellitus was diagnosed according to the American Diabetes Association criteria, which are as follows: a fasting plasma glucose level ≥126 mg/dL (or ≥200 mg/dL after a fasting period of \<10 hours); a hemoglobin A1c level ≥6.5%; the use of diabetes medications; or a history of diabetic retinopathy, neuropathy, or nephropathy.[13](#jah33655-bib-0013){ref-type="ref"} Dyslipidemia was defined as having a nonfasting serum total cholesterol level ≥220 mg/dL, low‐density lipoprotein cholesterol level ≥140 mg/dL, high‐density lipoprotein cholesterol level \<40 mg/dL, triglyceride level ≥150 mg/dL under fasting condition (or ≥300 mg/dL after \<10‐hour fast), or being under treatment.

Radiation Dose {#jah33655-sec-0013}
--------------

The estimated radiation dose received by each participant was based on the updated dosimetry system (DS02R1), which takes into account physical location and orientation at the time of the bombing as well as body shielding by terrain and organ shielding by the body.[14](#jah33655-bib-0014){ref-type="ref"}, [15](#jah33655-bib-0015){ref-type="ref"} For all analyses, skin dose (shielded kerma, or whole‐body, dose) was used in units of weighted gray (Gy), where the dose to an individual is the sum of γ ray dose plus 10 times the smaller neutron dose. Skin dose was selected a priori, assuming that total body irradiation may affect the entire vascular system, so that it is difficult to identify a single organ dose that is appropriate. A similar systemic effect is assumed for atherosclerosis risk factors.

Statistical Analysis {#jah33655-sec-0014}
--------------------

The χ^2^ test was used to compare demographic characteristics across dose categories. The relationship of PAD to covariates was assessed with logistic regression. That of UT was analyzed with a bivariate linear regression model fit with the generalized estimating equation approach allowing for correlation between UT in left and right lower legs. Covariates were centered at their sample means and scaled to reflect clinically meaningful units of change. Multivariate regression models for both outcomes were selected by stepwise elimination of the least‐significant effect with *P*≤0.05 at each step. After we arrived at the final model, we re‐tested each removed covariate one‐by‐one and found that none should be re‐entered. A nonparametric dose--response curve, the fractional polynomial plot, was constructed for radiation dose with predicted values of mean UT (mean of left and right measurements) and residuals from an ordinary linear‐regression model with adjustment for all other relevant covariates. Predicted values were also examined based on dose groups defined with cut points of 0, 0.001, 0.01, 0.1, 0.2, 0.5, 1.0, and 2.0 Gy. To determine whether the effect of a clinical condition on outcome is modified by therapeutic intervention, interaction variables were added to the regression analyses. The interaction variables were products of an indicator of each clinical condition (yes \[1\] or no \[0\] for hypertension, diabetes mellitus, and dyslipidemia) and history of medication (yes \[1\] or no \[0\]) for that condition. We performed 2 types of analysis: 1 a complete‐record analysis, where participants with missing values of variables in the regression model were excluded, and the other an analysis using as participants with multiple imputation. Missing values of covariates were imputed with fully conditional specification based on the method of sequential regression (chained equations)[16](#jah33655-bib-0016){ref-type="ref"}; 20 imputed data sets were created. We included all covariates (age, sex, examination city, and clinical conditions), as well as PAD, in the imputation model, which was based on ordinary regression for imputing values of continuous variables and a log‐linear model for imputing smoking status. Missing radiation doses were not imputed because radiation dose estimates depend on auxiliary variables used for dose reconstruction that, if missing, make it difficult to impute a dose estimate. All statistical tests were 2‐sided, and statistical significance was considered as *P*\<0.05, although effects were also judged based on their magnitude and 95% confidence intervals (CI). Analyses were performed with Stata (version 14.0, College Station, TX).

Results {#jah33655-sec-0015}
=======

Among the 3476 participants, 79 (2.3%) were identified as having PAD based on prior surgery (n=10) or ABI ≤1.0 (69) at the time of measurement in the study. Participant characteristics across dose categories are summarized in Table [1](#jah33655-tbl-0001){ref-type="table"}. The difference in distribution of age across dose strata reflects the expansion group added in 2008, which comprises people who are younger and have lower doses of radiation (mean age 70.7 years, mean dose 0.10 Gy) than the primary cohort (mean age 78.2 years, mean dose 0.52 Gy) (Table [2](#jah33655-tbl-0002){ref-type="table"}). Participants in higher dose groups tended to be hypertensive, dyslipidemic, and former smokers. For example, hypertension proportion is 67.0% in the 0 to 0.005 Gy group and 72.7% in the 2+ Gy group; dyslipidemia proportion is 63.0% and 68.7%, respectively; and current (ever) smoker proportion is 8.2% (32.7%) and 2.0% (42.4%), respectively. Heterogeneity in age by dose group, as explained above, can explain the differences, across dose categories, in blood pressure level and hypertension status, lipid data and dyslipidemia, and smoking status. Trends with dose were not apparent in any covariates except UT.

Age‐adjusted univariate odds ratios (OR) and multivariate OR of PAD for the individual covariates are shown in Table [3](#jah33655-tbl-0003){ref-type="table"}. Radiation was not associated with PAD: age‐adjusted univariate OR (response: OR has been defined in the earlier line) was 0.89 (95% CI 0.61--1.30, *P*=0.56) and multivariate adjusted OR was 0.83 (CI 0.57--1.21, *P*=0.35). The age‐adjusted univariate analysis indicated that UT was associated with radiation dose (slope coefficient 2.02 ms/Gy CI 0.66--3.37, *P*=0.004) (Table [4](#jah33655-tbl-0004){ref-type="table"}). After we adjusted for other covariates, this association was not statistically significant (1.09 ms/Gy CI −0.17--2.36, *P*=0.091) (Table [4](#jah33655-tbl-0004){ref-type="table"}), but the fractional polynomial plot of mean UT versus radiation dose (adjusted for other covariates) indicated possibly increasing UT with increasing dose level and appeared to be upwardly curving, without evidence of a threshold ([Figure](#jah33655-fig-0001){ref-type="fig"}). A sensitivity analysis in which radiation dose was also imputed (using an ordinary regression imputation model based only on the covariates and outcomes observed in the present study) produced qualitatively similar results and so did not suggest any strong bias caused by excluding data on participants with missing radiation dose.

###### 

Age‐Adjusted Univariate and Multivariable Analyses of Prevalent PAD[a](#jah33655-note-0006){ref-type="fn"}: The Adult Health Study (n=3476)[b](#jah33655-note-0007){ref-type="fn"}

  Variable                                                              Prevalent PAD                                                                 
  --------------------------------------------------------------------- --------------- ------------- ------- --------- -------------- ------ ------- ---------
  Sex (females)                                                         0.53            0.34          0.84    0.007     Not included                  
  Age, 5 y                                                              1.62            1.38          1.89    \<0.001   1.53           1.26   1.85    \<0.001
  Age squared, 5 y^2^                                                   1.02            0.92          1.13    0.92      Not included                  
  Radiation dose, Gy                                                    0.89            0.61          1.30    0.56      0.83           0.57   1.22    0.347
  Smoking                                                                                                                                             
  Current                                                               5.27            2.62          10.60   \<0.001   5.14           2.41   10.94   \<0.001
  Past                                                                  2.49            1.52          4.10    \<0.001   2.11           1.21   3.67    0.008
  Never                                                                 (reference)     (reference)                                                   
  Body mass index, kg/m^2^                                              1.04            0.97          1.11    0.27      Not included                  
  Systolic blood pressure, 10 mm Hg                                     1.09            0.96          1.23    0.19      Not included                  
  Diastolic blood pressure, 5 mm Hg                                     0.97            0.88          1.08    0.59      Not included                  
  Total cholesterol, 10 mg/dL                                           0.96            0.90          1.03    0.26      Not included                  
  HDL cholesterol, 5 mg/dL                                              0.88            0.81          0.96    0.002     Not included                  
  LDL cholesterol, 5 mg/dL                                              0.99            0.95          1.03    0.69      Not included                  
  log Triglyceride, log mg/dL                                           1.71            1.08          2.71    0.023     Not included                  
  White blood cell count, 100/dL                                        1.13            1.00          1.27    0.054     Not included                  
  log CRP, log μg/L                                                     1.32            1.10          1.59    0.002     1.21           0.99   1.49    0.065
  Estimated GFR, 10 mL/min per 1.73 m^2^                                0.71            0.62          0.82    \<0.001   0.77           0.67   0.89    \<0.001
  HbA1c, %                                                              1.05            1.02          1.07    \<0.001   Not included                  
  Hypertension                                                          1.40            0.57          3.42    0.46      1.41           0.73   2.70    0.309
  Hypertension medication[d](#jah33655-note-0009){ref-type="fn"}        2.34            1.27          4.33    0.007     Not included                  
  Diabetes mellitus                                                     1.41            0.63          3.15    0.41      1.83           1.09   3.07    0.021
  Diabetes mellitus medication[d](#jah33655-note-0009){ref-type="fn"}   2.98            1.79          4.98    \<0.001   Not included                  
  Dyslipidemia                                                          0.97            0.46          2.05    0.93      0.88           0.38   2.02    0.754
  Dyslipidemia medication[d](#jah33655-note-0009){ref-type="fn"}        2.32            1.36          3.98    0.002     2.66           1.27   5.59    0.010

ABI indicates ankle‐brachial index; CI, confidence interval; CRP, C‐reactive protein; GFR, glomerular filtration rate; HbA1c, hemoglobin A1c; HDL, high‐density lipoprotein; LDL, low‐density lipoprotein; OR, odds ratio; PAD, peripheral artery disease.

Prevalent cases of PAD were defined as participants who had ABI≤1.0 in either the right or left lower leg or who had had prior surgical or percutaneous revascularization procedures in the leg arteries.

Of 3476 participants, only 3217 were available for analyses focusing on radiation effects because of missing radiation dose estimates for the other participants.

OR of radiation exposure per Gy for PAD prevalence was calculated with adjustment for age at examination, smoking status, estimated GFR, CRP, diabetes mellitus, dyslipidemia, and hypertension, by using multivariable regression.

To determine whether the effect of a clinical condition on outcome is modified by therapeutic intervention, interaction variables were added to the regression analyses. The interaction variable for each condition was the product of an indicator of the condition (yes \[1\] or no \[0\] for hypertension, diabetes mellitus, and dyslipidemia) and history of medication (yes \[1\] or no \[0\]) for that condition.
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###### 

Age‐Adjusted Univariate and Multivariable Analyses of UT: The Adult Health Study (n=3476)[a](#jah33655-note-0011){ref-type="fn"}

  Variable                                                              UT \[ms\]                                                                    
  --------------------------------------------------------------------- ------------- ------------- ------- --------- -------------- ------- ------- ---------
  Sex (female)                                                          4.33          2.74          5.93    \<0.001   10.81          8.60    13.03   \<0.001
  Age, 5 y                                                              3.14          2.42          3.87    \<0.001   1.03           0.24    1.83    0.011
  Age squared, 5 y^2^                                                   0.70          0.18          1.22    0.008     0.78           0.27    1.30    0.003
  Radiation dose, Gy                                                    2.02          0.66          3.37    0.004     1.09           −0.17   2.36    0.091
  Smoking                                                                                                                                            
  Current smoker                                                        3.34          0.42          6.27    0.025     8.97           5.81    12.13   \<0.001
  Past smoker                                                           0.14          −1.58         1.85    0.87      5.83           3.58    8.08    \<0.001
  Never smoker                                                          (reference)   (reference)                                                    
  Body mass index, kg/m^2^                                              0.74          0.50          0.98    \<0.001   0.70           0.44    0.95    \<0.001
  Systolic blood pressure, 10 mm Hg                                     −0.16         −0.63         0.31    0.50      1.97           1.43    2.52    \<0.001
  Diastolic blood pressure, 5 mm Hg                                     −2.71         −3.10         −2.32   \<0.001   −3.55          −4.03   −3.08   \<0.001
  Total cholesterol, 10 mg/dL                                           −0.17         −0.40         0.07    0.16      0.75           −0.19   1.70    0.118
  HDL cholesterol, 5 mg/dL                                              −0.93         −1.18         −0.67   \<0.001   −1.47          −2.08   −0.85   \<0.001
  LDL cholesterol, 5 mg/dL                                              0.09          −0.05         0.22    0.22      −0.34          −0.82   0.15    0.174
  Triglyceride, Log                                                     4.68          3.04          6.32    \<0.001   −1.57          −4.14   1.00    0.230
  White blood cell count, 100/dL                                        0.33          −0.18         0.83    0.21      −0.58          −1.11   −0.05   0.032
  CRP, log μg/L                                                         1.10          0.39          1.81    0.003     0.21           −0.54   0.96    0.586
  Estimated GFR, 10 mL/min per 1.73 m^2^                                −0.94         −1.44         −0.44   \<0.001   −1.03          −1.52   −0.54   \<0.001
  HbA1c, %                                                              0.29          0.19          0.40    \<0.001   0.07           −0.04   0.18    0.207
  Hypertension                                                          −2.47         −5.02         0.07    0.057     Not included                   
  Hypertension medication[c](#jah33655-note-0013){ref-type="fn"}        2.92          1.18          4.65    0.001     Not included                   
  Diabetes mellitus                                                     3.17          0.31          6.02    0.030     Not included                   
  Diabetes mellitus medication[c](#jah33655-note-0013){ref-type="fn"}   7.03          4.67          9.38    \<0.001   Not included                   
  Dyslipidemia                                                          2.31          0.23          4.39    0.029     Not included                   
  Dyslipidemia medication[c](#jah33655-note-0013){ref-type="fn"}        4.38          2.57          6.19    \<0.001   Not included                   

CI indicates confidence interval; Coef, coefficient; CRP, C‐reactive protein; GEE, generalized estimating equation; HbA1c, hemoglobin A1c; HDL, high‐density lipoprotein; HT, hypertension; LDL, low‐density lipoprotein; UT, upstroke time.

Of 3476 participants, only 3217 were available for analyses focusing on radiation effects because of missing radiation dose estimates for the other participants.

The GEE regression method was used with UT in right and left legs as a bivariate outcome. Change in UT with 1 Gy radiation exposure was calculated with adjustment for age at examination, smoking status, body mass index, systolic blood pressure, diastolic blood pressure, total cholesterol, HDL cholesterol, LDL cholesterol, triglyceride, white blood cell count, CRP, and estimated GFR.

To determine whether the effect of a clinical condition on outcome is modified by therapeutic intervention, interaction variables were added to the regression analyses. The interaction variable for each condition was the product of an indicator of the condition (yes \[1\] or no \[0\] for hypertension, diabetes mellitus, and dyslipidemia) and history of medication (yes \[1\] or no \[0\]) for that condition.
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![Upstroke time (UT) by radiation dose---The Adult Health Study (n=3476).\* A nonparametric dose--response curve based on fractional‐polynomial smoothing, with predicted mean values of UT obtained from the generalized estimating equation model using dose groups. Dose groups were defined by the cut points 0, 0.001, 0.01, 0.1, 0.2, 0.5, 1.0, and 2.0. Both the estimated dose response and its lower confidence band give the suggestion of a trend with increasing dose level, consistent with the regression term for continuous dose (Tables [2](#jah33655-tbl-0002){ref-type="table"} and [3](#jah33655-tbl-0003){ref-type="table"}). Mean UT (![](JAH3-7-e008921-g002.jpg "image")) and 95% confidence intervals (+) for dose group are illustrated. \*Of 3476 participants, 3217 were available for analyses focusing on radiation effects because of missing radiation dose estimates.](JAH3-7-e008921-g001){#jah33655-fig-0001}

Current smoking had the strongest influence on PAD prevalence (multivariate adjusted OR 5.14, CI 2.41--10.9); past smoking had a lower effect (OR 2.11, CI 1.21--3.67, *P*\<0.001) (Table [3](#jah33655-tbl-0003){ref-type="table"}). As for the clinical conditions, diabetes mellitus (OR 1.83, CI 1.09--3.07, *P*=0.008) and medication for dyslipidemia (OR 2.66, CI 1.27--5.59, *P*=0.010) had large effects on PAD. Although hypertensive status was associated with an increase in UT (Table [4](#jah33655-tbl-0004){ref-type="table"}), the effects of clinical covariates mostly disappeared during the stepwise‐elimination regression procedure. Instead, multivariate adjusted coefficients of systolic blood pressure and diastolic blood pressure were statistically significant for UT: multivariate adjusted coefficients were 1.97 (CI 1.43--2.52, *P*\<0.001) for systolic blood pressure and −3.55 (CI −4.03 to −3.08, *P*\<0.001) for diastolic blood pressure. Smoking markedly prolonged UT: multivariate adjusted coefficient for current smoking was 8.97 (CI 5.81--12.1, *P*\<0.001) and that for past smoking was 5.83 (CI 3.58--8.08, *P*\<0.001).

Discussion {#jah33655-sec-0016}
==========

In this cross‐sectional clinical study, we did not find a relationship between radiation exposure and PAD prevalence based on low and borderline ABI (≤1.0) or a history of revascularization among the Japanese atomic‐bomb survivors with \<4 Gy whole body exposures. Prolonged UT, a sensitive marker for stenosis, was correlated with radiation dose but was not statistically significant (*P*=0.091). An apparent radiation dose response for UT could not be ruled out and warrants further study.

Past studies indicated an excess risk of circulatory disease in Japanese atomic‐bomb survivors (\<5 Gy),[1](#jah33655-bib-0001){ref-type="ref"}, [2](#jah33655-bib-0002){ref-type="ref"} and a 14% per Gy excess risk of death because of all heart disease was observed in the Life Span Study cohort with follow‐up from 1950 to 2008.[1](#jah33655-bib-0001){ref-type="ref"} Results of several other studies of radiation‐exposed groups (with doses \<0.5 Gy) remain controversial[3](#jah33655-bib-0003){ref-type="ref"}, [4](#jah33655-bib-0004){ref-type="ref"}; significant associations between external radiation exposure and ischemic heart disease risk were indicated in the Russian Federation Mayak nuclear workers study (mortality and incidence), Chernobyl emergency workers study (mortality), and INWORKS (mortality), whereas significant radiation risks of ischemic heart disease mortality were not found in the German uranium miner study, French nuclear worker study, studies of Eldorado uranium miners and processing workers, the third analysis from the UK national registry for radiation workers, or the International Agency for Research on Cancer 15‐country nuclear worker study. The controversy may stem from differences in radiation risk estimates based on different ethnic groups and different exposure settings. The Japanese atomic‐bomb survivors, our study population, had a single acute exposure, unlike nuclear workers, who had protracted chronic low‐dose‐rate exposures. In addition, background risk factors in our population differ from those in Western populations. Mechanisms of atherosclerosis might include radiation‐related tissue effects,[6](#jah33655-bib-0006){ref-type="ref"} but the lack of strong evidence of atherosclerosis risk at low radiation doses prevents a clear conclusion about the causal association.

PAD, together with coronary artery disease and cerebrovascular disease, is a polyvascular disease. Radiation‐exposed subjects may be at excess risk of developing subsequent PAD, but a long‐term risk after exposure to low‐to‐moderate doses has not been reported. Onset of PAD more than 65 years after the time of atomic‐bomb radiation exposure may be especially meaningful with regard to the increased use of radiotherapy at younger ages and increased likelihood of developing PAD in later life.

Given that an association between radiation dose and risk of peripheral arteriosclerosis is plausible, an explanation for such association is needed but is far from clear. At high doses---≈30 to 40 Gy---there is well‐established evidence of direct damage to the circulatory system, predominantly because of the corresponding response to excessive cell killing.[17](#jah33655-bib-0017){ref-type="ref"} In contrast, epidemiological and clinical evidence indicates that the mechanisms associated with low‐to‐moderate doses of ionizing radiation (\<500 mGy) are different.[17](#jah33655-bib-0017){ref-type="ref"} In studies of the AHS cohort, radiation exposure has been associated with vascular calcification but not with intima‐media thickness.[18](#jah33655-bib-0018){ref-type="ref"} A potential mechanism of arterial alteration after low‐to‐moderate‐dose irradiation remains unclear. Long‐lasting immune dysfunction, perturbed T‐cell homeostasis, or pro‐inflammatory status in the atomic‐bomb survivors[19](#jah33655-bib-0019){ref-type="ref"}, [20](#jah33655-bib-0020){ref-type="ref"} may contribute to subsequent vascular damage.[21](#jah33655-bib-0021){ref-type="ref"} Furthermore, elevated blood pressure[22](#jah33655-bib-0022){ref-type="ref"} or hypertension[23](#jah33655-bib-0023){ref-type="ref"} among the atomic‐bomb survivors might further promote arterial changes linked with atherosclerotic changes.

In the current study, 2.3% of participants were identified as PAD cases on the basis of low or borderline ABI (ABI ≤1.0) or postrevascularization, but those with lower ABI (ABI \<0.9) constituted only 0.5% of our study participants, whereas they constitute 1.7% to 4.3% of the general Japanese population[24](#jah33655-bib-0024){ref-type="ref"}, [25](#jah33655-bib-0025){ref-type="ref"}, [26](#jah33655-bib-0026){ref-type="ref"} and 3.6% to 14% of the Western population[27](#jah33655-bib-0027){ref-type="ref"}, [28](#jah33655-bib-0028){ref-type="ref"}, [29](#jah33655-bib-0029){ref-type="ref"} (Table [5](#jah33655-tbl-0005){ref-type="table"}). Prevalence in Japanese groups is lower than that in Western countries, which may be linked with the fact that lower body mass index in Japanese might be associated with a lower prevalence of atherosclerosis. PAD prevalence is strongly age related,[30](#jah33655-bib-0030){ref-type="ref"} but elderly participants in our study had lower prevalence than other Japanese groups. Although a clear explanation was not found, this could be attributable to 3 reasons. First, it is plausible that healthy survivors were more likely to attend our clinical examination. In other words, because of the high mortality from PAD,[31](#jah33655-bib-0031){ref-type="ref"}, [32](#jah33655-bib-0032){ref-type="ref"} PAD patients may have died before our cross‐sectional survey. Indeed, age‐specific rates in the AHS were lower in the elderly group: prevalence at 60 to 69 years of age was 1.2% in the KOPS (Kyushu and Okinawa Population Study)[26](#jah33655-bib-0026){ref-type="ref"} versus 0.9% in the AHS, 2.3% versus 1.9% at 70 to 79 years of age, and 6.7% versus 4.7% at 80+ years of age. Second, our study included very few smokers because females are over‐represented relative to males in our cohort (58.9%), whereas the sex distribution was 40% men and 10% women in the 2007 Japan National Health and Nutrition Survey.[33](#jah33655-bib-0033){ref-type="ref"} Third, the atomic‐bomb survivors have received social services including periodic health examinations and cancer screening, which should encourage improved lifestyles and help reduce the risk of developing PAD.

###### 

Studies of PAD and its Risk Factors in Japan and Western Countries

  Characteristic            Adult Health Study[a](#jah33655-note-0015){ref-type="fn"}   Tanno‐Sobetsu Study[25](#jah33655-bib-0025){ref-type="ref"}   The Kyusyu and Okinawa Population Survey (KOPS)[26](#jah33655-bib-0026){ref-type="ref"}   Cardiovascular Risk Survey[24](#jah33655-bib-0024){ref-type="ref"}   Multi‐Ethnic Study of Atherosclerosis (MESA)[27](#jah33655-bib-0027){ref-type="ref"}   Rotterdam Study[28](#jah33655-bib-0028){ref-type="ref"}   Framingham Offspring Study[29](#jah33655-bib-0029){ref-type="ref"}                   
  ------------------------- ----------------------------------------------------------- ------------------------------------------------------------- ----------------------------------------------------------------------------------------- -------------------------------------------------------------------- -------------------------------------------------------------------------------------- --------------------------------------------------------- -------------------------------------------------------------------- ------- ------- ------------
  ABI cutoff                ≤1.0                                                        \<0.9                                                         \<0.9                                                                                     ≤0.9                                                                 ≤0.9                                                                                   \<0.9                                                     ≤0.9                                                                 \<0.9   \<0.9   0.9 to 1.0
  PAD prevalence            2.3                                                         0.5                                                           2.7                                                                                       1.71                                                                 4.3                                                                                    6.5                                                       4.1                                                                  19      3.6     7.1
  N                         3476                                                        1398                                                          2402                                                                                      726[b](#jah33655-note-0016){ref-type="fn"}                           6653                                                                                   6450[c](#jah33655-note-0017){ref-type="fn"}               3313                                                                                 
  Age (mean, y)             74.8                                                        64.2                                                          64.9                                                                                      66.8                                                                 62.2                                                                                   69.5                                                      59.1                                                                                 
  Diabetes mellitus \[%\]   21.7                                                        9.2                                                           ...                                                                                       12.5                                                                 14.0                                                                                   8.1                                                       10.1                                                                                 
  Hypertension \[%\]        65.8                                                        51.6                                                          49.3                                                                                      56.5                                                                 44.2                                                                                   52.8                                                      42.1                                                                                 
  Current smoker \[%\]      8.4                                                         35.8                                                          11.5                                                                                      41.5                                                                 13.1                                                                                   20.1                                                      15.8                                                                                 
  BMI \[kg/m^2^\]           22.9                                                        23.8                                                          22.9                                                                                      23.5                                                                 28.2                                                                                   26.3                                                      28.0                                                                                 

Mean age, mean BMI, and percentages with risk factors were extracted from several reports that had different levels of adjustment: sex‐specific data from the Tanno‐Sobetsu study[25](#jah33655-bib-0025){ref-type="ref"} and the Rotterdam Study,[28](#jah33655-bib-0028){ref-type="ref"} age‐sex adjusted data by ethnic group from the MESA study,[27](#jah33655-bib-0027){ref-type="ref"} and data stratified by ABI level from the Cardiovascular Risk Study[24](#jah33655-bib-0024){ref-type="ref"} and the Framingham Offspring Study.[29](#jah33655-bib-0029){ref-type="ref"} ABI indicates ankle‐brachial blood pressure index; BMI, body mass index; PAD, peripheral artery disease.

Participants of the current study derive from the Adult Health Study cohort[7](#jah33655-bib-0007){ref-type="ref"}, [8](#jah33655-bib-0008){ref-type="ref"} of Japanese survivors of the atomic bombing.

Men aged 60 to 79 years.

Excluding people with ABI\>1.4.
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Such low prevalence as was observed in our participants can cause lack of power to detect the impact of radiation exposure on long‐term PAD prevalence. Small numbers of atomic‐bomb survivors exposed to high doses further reduces power. In light of these issues, the potential association between low‐to‐moderate doses of radiation exposure and PAD deserves further consideration.

Our investigation also failed to find a strong association between UT and radiation dose (Table [4](#jah33655-tbl-0004){ref-type="table"}), but there was an upward tendency in UT with dose ([Figure](#jah33655-fig-0001){ref-type="fig"}). In the multiple regression equation for UT change, the stepwise procedure selected blood pressure measurements as explanatory variables but not hypertension history. This can be explained by the fact that UT is acquired from the pulse wave technique: UT is more likely to depend on hemodynamics or high blood pressures than on hypertension (a dichotomous variable) per se. Furthermore, the estimated coefficients were positive for systolic pressure and negative for diastolic pressure, which agrees with evidence that lowering diastolic pressure[34](#jah33655-bib-0034){ref-type="ref"} and elevating systolic pressure[35](#jah33655-bib-0035){ref-type="ref"} are a consequence of reduced aortic elasticity. This evidence indicates that prolonged UT might be related to relatively mild atherosclerosis, and this feature of UT could identify patients at high risk but missed by the ABI method.[11](#jah33655-bib-0011){ref-type="ref"} Our findings with UT suggest that the atomic‐bomb survivors may be at risk of vascular damage even if not severe occlusion. The advanced method for measuring UT has been available only for a decade, and factors that might affect UT are not yet fully clear. Considering both of our findings---no significant association between radiation dose and PAD prevalence but a suggestive radiation dose‐response pattern in UT---low‐to‐moderate radiation doses may promote stenotic changes in arteries but not such severe changes as would lead to clinically apparent ischemia in the lower extremities. These end points were not confirmed with angiography as the AHA guidelines recommend, so careful interpretation of the current findings is needed.

Radiation dose and age are confounded because their joint distribution differs according to whether participants belong to the younger expansion group added in 2008. In the primary cohort, mean age was 78.2 years and mean dose was 0.52 Gy (n=1788), but in the younger expansion group, mean age was 70.7 years and mean dose was 0.10 Gy (n=1688) (Table [2](#jah33655-tbl-0002){ref-type="table"}). This is the reason why we adjusted for age when estimating the univariate effects reported in Tables [2](#jah33655-tbl-0002){ref-type="table"} and [3](#jah33655-tbl-0003){ref-type="table"}. We also conducted analogous multivariate analyses with data from only the primary cohort, excluding the 2008 expansion group; the values of radiation‐related OR for PAD and radiation‐related change in UT were similar to those shown in Tables [2](#jah33655-tbl-0002){ref-type="table"} and [3](#jah33655-tbl-0003){ref-type="table"} (results not shown).

We note several strengths and limitations of our study. The primary limitation is that diagnosis of PAD and assessment of UT was not confirmed by angiography, but American Heart Association guidelines recommend angiography as a PAD evaluation method. The use of oscillometric ABI may underestimate the prevalence of PAD,[36](#jah33655-bib-0036){ref-type="ref"} particularly in our elderly cohort.[9](#jah33655-bib-0009){ref-type="ref"} The pulse wave recording technique used in our study may be influenced by factors other than vessel patency, such as heart rate. The small number of PAD cases might be cause for concern about bias in the logistic regression maximum likelihood estimates, although a comparison between crude and multivariable estimates in Table [3](#jah33655-tbl-0003){ref-type="table"} does not reveal any obvious problems; furthermore, a separate multivariable fit with Firth\'s logistic regression[37](#jah33655-bib-0037){ref-type="ref"} (data not shown) produced estimates virtually identical to those in Table [3](#jah33655-tbl-0003){ref-type="table"}, which suggests that small‐sample bias is not likely present. Finally, our sample size of 99 in the high‐dose group (\>2 Gy) could be insufficient to provide adequate power for finding a dose response with PAD, but the estimated odds ratio for 1 Gy is \<1.0 and the upper bound of the 95% CI (1.22), the highest value of the OR compatible with the data, is not large. Despite these limitations, this study is the first report of long‐lasting risk of PAD after exposure to low‐to‐moderate doses of radiation. The primary strength of our study is that data on ABI and pulse wave were collected in a clinical setting with the VP‐2000 device, which provides accurate measurements with minimal need for examiner technical skill.[9](#jah33655-bib-0009){ref-type="ref"}, [36](#jah33655-bib-0036){ref-type="ref"}, [38](#jah33655-bib-0038){ref-type="ref"} Dose reconstruction is another strength; estimation of radiation doses follows a system of quantification based on theoretical physics and interviews of many survivors regarding location and shielding.[14](#jah33655-bib-0014){ref-type="ref"}, [15](#jah33655-bib-0015){ref-type="ref"} Among large cohort studies, exposure reconstruction in the atomic‐bomb survivor cohort is unusually precise.

In conclusion, a radiation‐related change in PAD prevalence was not evident, although stenotic changes were suggested. Further investigation is needed to determine whether prolonged UT reflects radiation‐induced vascular damage.
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